Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2020 3
2021 4
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Showing results for vitali, p. Kim
Your search for Vitaliy P. Kim retrieved no results
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. Horn L, et al. N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280641 Clinical Trial.
At a median follow-up of 13.9 months, the median overall survival was 12.3 months in the atezolizumab group and 10.3 months in the placebo group (hazard ratio for death, 0.70; 95% confidence interval [CI], 0.54 to 0.91; P=0.007). The median progression-free survival was 5. …
At a median follow-up of 13.9 months, the median overall survival was 12.3 months in the atezolizumab group and 10.3 months in the placebo g …
Conflict of Interest Disclosures.
[No authors listed] [No authors listed] Global Spine J. 2023 May;13(2_suppl):568S-591S. doi: 10.1177/21925682231173597. Global Spine J. 2023. PMID: 37222100 Free PMC article. No abstract available.
Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study.
COVIDSurg Collaborative. COVIDSurg Collaborative. Lancet Oncol. 2021 Nov;22(11):1507-1517. doi: 10.1016/S1470-2045(21)00493-9. Epub 2021 Oct 5. Lancet Oncol. 2021. PMID: 34624250 Free PMC article. Clinical Trial.
Light restrictions were associated with a 0.6% non-operation rate (26 of 4521), moderate lockdowns with a 5.5% rate (201 of 3646; adjusted hazard ratio [HR] 0.81, 95% CI 0.77-0.84; p<0.0001), and full lockdowns with a 15.0% rate (1775 of 11 827; HR 0.51, 0.50-0.53; p …
Light restrictions were associated with a 0.6% non-operation rate (26 of 4521), moderate lockdowns with a 5.5% rate (201 of 3646; adjusted h …
Extracorporeal Life Support Organization Registry International Report 2022: 100,000 Survivors.
Tonna JE, Boonstra PS, MacLaren G, Paden M, Brodie D, Anders M, Hoskote A, Ramanathan K, Hyslop R, Fanning JJ, Rycus P, Stead C, Barrett NA, Mueller T, Gómez RD, Malhotra Kapoor P, Fraser JF, Bartlett RH, Alexander PMA, Barbaro RP; Extracorporeal Life Support Organization (ELSO) Member Centers Group. Tonna JE, et al. ASAIO J. 2024 Feb 1;70(2):131-143. doi: 10.1097/MAT.0000000000002128. Epub 2024 Jan 5. ASAIO J. 2024. PMID: 38181413
The impact of surgical delay on resectability of colorectal cancer: An international prospective cohort study.
COVIDSurg Collaborative. COVIDSurg Collaborative. Colorectal Dis. 2022 Mar 14;24(6):708-26. doi: 10.1111/codi.16117. Online ahead of print. Colorectal Dis. 2022. PMID: 35286766 Free PMC article.

Delayed patients had higher unadjusted rates of complete resection (93.7% vs. 91.9%, P = 0.032) and lower rates of emergency surgery (4.5% vs. 22.5%, P < 0.001). After adjustment, delay was not associated with a lower rate of complete resection (OR 1.18, 95% CI 0

…
Delayed patients had higher unadjusted rates of complete resection (93.7% vs. 91.9%, P = 0.032) and lower rates of emergency surgery …
Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic.
STARSurg Collaborative and COVIDSurg Collaborative. STARSurg Collaborative and COVIDSurg Collaborative. Br J Surg. 2021 Dec 1;108(12):1448-1464. doi: 10.1093/bjs/znab336. Br J Surg. 2021. PMID: 34871379 Free PMC article.

The pulmonary complication rate was similar (7.1 per cent (216 of 3031) versus 6.3 per cent (274 of 4371); P = 0.158) but the mortality rate was significantly higher (0.7 per cent (20 of 3031) versus 2.0 per cent (87 of 4371); P < 0.001) among patients who had su

…
The pulmonary complication rate was similar (7.1 per cent (216 of 3031) versus 6.3 per cent (274 of 4371); P = 0.158) but the mortali …
Safety and efficacy of non-steroidal anti-inflammatory drugs to reduce ileus after colorectal surgery.
EuroSurg Collaborative. EuroSurg Collaborative. Br J Surg. 2020 Jan;107(2):e161-e169. doi: 10.1002/bjs.11326. Epub 2019 Oct 9. Br J Surg. 2020. PMID: 31595986 Free article.
After adjustment for baseline differences, the mean time to gastrointestinal recovery did not differ significantly between patients who received NSAIDs and those who did not (4.6 versus 4.8 days; hazard ratio 1.04, 95 per cent c.i. 0.96 to 1.12; P = 0.360). There were no s …
After adjustment for baseline differences, the mean time to gastrointestinal recovery did not differ significantly between patients who rece …
Safety of hospital discharge before return of bowel function after elective colorectal surgery.
EuroSurg Collaborative. EuroSurg Collaborative. Br J Surg. 2020 Apr;107(5):552-559. doi: 10.1002/bjs.11422. Epub 2020 Jan 24. Br J Surg. 2020. PMID: 31976560

The median duration of hospital stay for patients discharged before and after return of bowel function was 5 (i.q.r. 4-7) and 7 (6-8) days respectively (P < 0.001). There were no significant differences in rates of readmission between these groups (6.6 versus 8.0 per ce

…
The median duration of hospital stay for patients discharged before and after return of bowel function was 5 (i.q.r. 4-7) and 7 (6-8) days r …
Timing of nasogastric tube insertion and the risk of postoperative pneumonia: an international, prospective cohort study.
EuroSurg Collaborative. EuroSurg Collaborative. Colorectal Dis. 2020 Dec;22(12):2288-2297. doi: 10.1111/codi.15311. Epub 2020 Sep 18. Colorectal Dis. 2020. PMID: 34092023
After adjustment for confounding factors, no significant difference in pneumonia rates was detected between the prophylactic and reactive NGT groups (odds ratio 1.03, 95% CI 0.56-1.87, P = 0.932). CONCLUSION: In patients who required the insertion of a NGT after surgery, p …
After adjustment for confounding factors, no significant difference in pneumonia rates was detected between the prophylactic and reactive NG …
Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
Montgomery H, Hobbs FDR, Padilla F, Arbetter D, Templeton A, Seegobin S, Kim K, Campos JAS, Arends RH, Brodek BH, Brooks D, Garbes P, Jimenez J, Koh GCKW, Padilla KW, Streicher K, Viani RM, Alagappan V, Pangalos MN, Esser MT; TACKLE study group. Montgomery H, et al. Lancet Respir Med. 2022 Oct;10(10):985-996. doi: 10.1016/S2213-2600(22)00180-1. Epub 2022 Jun 7. Lancet Respir Med. 2022. PMID: 35688164 Free PMC article. Clinical Trial.
Severe COVID-19 or death occurred in 18 (4%) of 407 participants in the tixagevimab-cilgavimab group versus 37 (9%) of 415 participants in the placebo group (relative risk reduction 50.5% [95% CI 14.6-71.3]; p=0.0096). The absolute risk reduction was 4.5% (95% CI 1.1-8.0; …
Severe COVID-19 or death occurred in 18 (4%) of 407 participants in the tixagevimab-cilgavimab group versus 37 (9%) of 415 participants in t …
12 results